Sex differences in patients with heart failure and mildly reduced left ventricular ejection fraction

Zhican Liu,Yunlong Zhu,Sihao Chen,Mingxin Wu,Haobo Huang,Ke Peng,Lingling Zhang,Wenjiao Zhao,Xin Peng,Na Li,Hui Zhang,Yuying Zhou,Yiqun Peng,Jie Fan,Jianping Zeng
DOI: https://doi.org/10.1038/s41598-023-33733-8
IF: 4.6
2023-04-26
Scientific Reports
Abstract:Abstract Clinical studies on heart failure with mildly reduced left ventricular ejection fraction (HFmrEF) have gradually increased. However, studies on the prognostic differences between men and women among patients with HFmrEF are few, and no evidence on sex differences in such patients exists. Therefore, we retrospectively assessed the data of patients with HFmrEF using propensity score-matched analysis (PSMA). A total of 1691 patients with HFmrEF were enrolled in the Outcome of Discharged HFmrEF Patients study (OUDI-HF study), which included 1095 men and 596 women. After propensity score matching, we compared the difference in cardiovascular (CV) events (cardiovascular death or heart failure readmission) and all-cause mortality at 90 days and 1 year after discharge between men and women using Kaplan–Meier analysis and Cox regression. After PSMA, men with HFmrEF were 2.2 times more likely to die at 90 days than women with HFmrEF [hazard ratio (HR) 1.88; 95% confidence interval (95% CI) 1.03–3.46; P = 0.041]. However, there was no difference in the 90-day CV events (HR 0.96; 95% CI 0.75–1.22; P = 0.718). Similarly, there was no difference in all-cause mortality (HR 1.16; 95% CI 0.81–1.65; P = 0.417) and CV events (HR 0.98; 95% CI 0.83–1.16; P = 0.817) between men and women after 1 year. Among the patients with HFmrEF, men had a higher 90-day risk of all-cause mortality than women after hospital discharge, and this risk disappeared after 1 year. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT05240118 ( ESC Heart Failure . (2022). doi: https://doi.org/10.1002/ehf2.14044 ).
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to explore the gender differences in all - cause mortality and the incidence of cardiovascular events within 90 days and 1 year after discharge between male and female patients with heart failure and mildly reduced left ventricular ejection fraction (HFmrEF). Through retrospective analysis, the study used propensity score - matching analysis (PSMA) to balance the baseline characteristics between the two groups in order to reduce the influence of potential confounding factors. The study found that after PSMA, the 90 - day all - cause mortality risk in male HFmrEF patients was significantly higher than that in female patients, but this difference disappeared after 1 year. In addition, the study also pointed out that there were no significant differences between men and women in major cardiovascular events at 90 days and 1 year. Specifically, the main findings of the study include: - **90 - day all - cause mortality**: After PSMA, the 90 - day all - cause mortality in male HFmrEF patients was significantly higher than that in female patients (HR 1.88; 95% CI 1.03 - 3.46; P = 0.041). - **1 - year all - cause mortality**: After PSMA, there was no significant difference in 1 - year all - cause mortality between male and female patients (HR 1.16; 95% CI 0.81 - 1.65; P = 0.417). - **90 - day and 1 - year cardiovascular events**: After PSMA, there were no significant differences in the incidence of cardiovascular events at 90 days and 1 year between male and female patients (90 days: HR 0.96; 95% CI 0.75 - 1.22; P = 0.718; 1 year: HR 0.98; 95% CI 0.83 - 1.16; P = 0.817). These results indicate that male HFmrEF patients have a higher short - term survival risk after discharge, especially within 90 days. Therefore, the study suggests that more attention and management should be given to male HFmrEF patients in the early stage after discharge. At the same time, the study also emphasizes the importance of further research to better understand the gender - related risk differences in heart failure and thus develop more effective treatment strategies.